Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;6(5):101002.
doi: 10.1016/j.lanmic.2024.101002. Epub 2024 Nov 13.

Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials

Xin Hui S Chan  1 , Ilsa L Haeusler  2 , Bennett J K Choy  2 , Md Zakiul Hassan  3 , Junko Takata  4 , Tara P Hurst  2 , Luke M Jones  5 , Shanghavie Loganathan  6 , Elinor Harriss  7 , Jake Dunning  8 , Joel Tarning  9 , Miles W Carroll  5 , Peter W Horby  10 , Piero L Olliaro  10
Affiliations

Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials

Xin Hui S Chan et al. Lancet Microbe. 2025 May.

Abstract

Nipah virus disease is a bat-borne zoonosis with person-to-person transmission, a case-fatality rate of 38-75%, and well recognised potential to cause a pandemic. The first reported outbreak of Nipah virus disease occurred in Malaysia and Singapore in 1998, which has since been followed by multiple outbreaks in Bangladesh and India. To date, no therapeutics or vaccines have been approved to treat Nipah virus disease, and only few such candidates are in development. In this Review, we aim to assess the safety and efficacy of the therapeutic options (monoclonal antibodies and small molecules) for Nipah virus disease and other henipaviral diseases to support prioritisation of drug candidates for further evaluation in clinical trials. At present, sufficient evidence exists to suggest trialling 1F5, m102.4, and remdesivir (alone or in combination) for prophylaxis and early treatment of Nipah virus disease. In addition to well designed clinical efficacy trials, in-vivo pharmacokinetic-pharmacodynamic studies are needed to optimise the selection and dosing of therapeutic candidates in animal challenge and natural human infection.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests We declare no competing interests.

Figures

Figure
Figure
PRISMA flow chart
See this image and copyright information in PMC

References

    1. Goh KJ, Tan CT, Chew NK, et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med. 2000;342:1229–1235. - PubMed
    1. Luby SP, Rahman M, Hossain MJ, et al. Foodborne transmission of Nipah virus, Bangladesh. Emerg Infect Dis. 2006;12:1888–1894. - PMC - PubMed
    1. Nikolay B, Salje H, Hossain MJ, et al. Transmission of Nipah virus—14 years of investigations in Bangladesh. N Engl J Med. 2019;380:1804–1814. - PMC - PubMed
    1. Chowdhury S, Khan SU, Crameri G, et al. Serological evidence of henipavirus exposure in cattle, goats and pigs in Bangladesh. PLoS Negl Trop Dis. 2014;8 - PMC - PubMed
    1. Islam A, Cannon DL, Rahman MZ, et al. Nipah virus exposure in domestic and peridomestic animals living in human outbreak sites, Bangladesh, 2013–2015. Emerg Infect Dis. 2023;29:393–396. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources